What it's for (Indications)
- Epoetin beta is a recombinant human erythropoietin indicated for the treatment of symptomatic anemia associated with chronic renal failure in adult and pediatric patients, including those on dialysis and those not yet on dialysis.
- It is also utilized for the treatment of anemia and to reduce transfusion requirements in adult patients with non-myeloid malignancies receiving myelosuppressive chemotherapy.
- Furthermore, epoetin beta is indicated for increasing the yield of autologous blood for transfusion in adult patients enrolled in a pre-donation program, particularly when blood conservation is crucial and patients face a high likelihood of requiring transfusions.
- It also has specific indications for the treatment of anemia in adult patients with myelodysplastic syndromes (MDS) of low or intermediate-1 risk with symptomatic anemia and low serum erythropoietin levels (<200 mU/mL).
- This broad applicability underscores its role in managing diverse forms of anemia where erythropoietin deficiency or inadequate response is a contributing factor, aiming to improve quality of life and clinical outcomes by increasing red blood cell mass and hemoglobin levels.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | The dosage of epoetin beta is highly individualized and must be carefully titrated based on the specific indication, the patient's body weight, baseline hemoglobin levels, target hemoglobin range, and individual therapeutic response. Administration can be either by subcutaneous (SC) or intravenous (IV) injection. For adults with chronic renal failure, initial doses typically range from 50 to 100 International Units (IU) per kilogram of body weight, administered three times weekly, with subsequent adjustments made to maintain hemoglobin levels within a specified target range, usually between 10 g/dL and 12 g/dL. In patients with chemotherapy-induced anemia, common starting regimens involve 150 IU/kg SC three times weekly or 450 IU/kg SC once weekly, with dosage modifications based on the rise in hemoglobin. Monitoring of hemoglobin, iron status, and clinical response is crucial throughout therapy to ensure efficacy and safety, preventing the risks associated with excessively high hemoglobin levels. The specific dosing schedule and target hemoglobin must adhere strictly to established guidelines and prescriber discretion. |
Safety & Warnings
Common Side Effects
- Epoetin beta therapy can be associated with a range of side effects, both common and serious, requiring careful patient monitoring.
- Common side effects include hypertension, headache, arthralgia, fever, fatigue, rash, nausea, vomiting, and diarrhea.
- Hypertension is particularly prevalent and necessitates rigorous blood pressure monitoring and management to prevent complications.
- More serious adverse events include thromboembolic events such as deep vein thrombosis (DVT), pulmonary embolism (PE), myocardial infarction (MI), and stroke, especially when hemoglobin targets exceed recommended levels.
- Pure Red Cell Aplasia (PRCA), characterized by a sudden decrease in hemoglobin and red blood cell precursors, can occur, often associated with neutralizing antibodies to erythropoietin, predominantly with subcutaneous administration.
- Seizures have also been reported, especially during the initial months of treatment.
- Hypersensitivity reactions, ranging from mild skin reactions to severe anaphylaxis, are possible.
- An increased risk of tumor progression or recurrence has been observed in some cancer patients.
- Therefore, a comprehensive risk-benefit assessment and close patient surveillance are imperative throughout the treatment course to mitigate potential risks.
Serious Warnings
- Black Box Warning: **WARNING: INCREASED RISK OF DEATH, MYOCARDIAL INFARCTION, STROKE, VENOUS THROMBOEMBOLISM, AND THROMBOSIS OF VASCULAR ACCESS IN CHRONIC KIDNEY DISEASE PATIENTS; INCREASED RISK OF DEATH AND/OR TUMOR PROGRESSION OR RECURRENCE IN CANCER PATIENTS; PURE RED CELL APLASIA.** In patients with Chronic Kidney Disease (CKD), epoetin beta and other Erythropoiesis-Stimulating Agents (ESAs) increase the risk of death, serious cardiovascular events (including myocardial infarction and stroke), and thrombosis of vascular access when administered to target hemoglobin levels exceeding 11 g/dL. Use the lowest epoetin beta dose sufficient to reduce the need for red blood cell transfusions and avoid levels above 11 g/dL, as higher levels have not been shown to provide additional benefit and may increase risks. Monitoring hemoglobin levels closely and adjusting dosage are crucial to maintaining these safety parameters. For patients with cancer, ESAs increase the risk of death and/or tumor progression or recurrence in some clinical studies, particularly in patients with breast cancer, non-small cell lung cancer, head and neck cancer, and lymphoid malignancy. This includes an increased risk of death in cancer patients receiving chemotherapy when ESAs are administered to target hemoglobin levels greater than 12 g/dL. ESAs are not indicated for use in patients with cancer receiving chemotherapy when the anticipated outcome is cure. Discontinue epoetin beta when the chemotherapy course is completed. The decision to use epoetin beta in cancer patients must involve a careful discussion of the potential risks versus benefits. Serious thromboembolic events, including deep vein thrombosis (DVT), pulmonary embolism (PE), and arterial thromboses (e.g., myocardial infarction, stroke), have been reported in patients treated with ESAs. The risk of these events is higher in patients with CKD and cancer. Prophylactic anticoagulation may be necessary in certain clinical settings. Cases of Pure Red Cell Aplasia (PRCA) with neutralizing antibodies to erythropoietin have been observed in patients treated with epoetin beta. Discontinue epoetin beta and evaluate patients for PRCA if severe anemia develops suddenly or if the patient develops neutralizing antibodies to erythropoietin; do not switch to another ESA as antibodies may cross-react.
- Epoetin beta carries several significant warnings that healthcare providers must consider to ensure patient safety.
- Of paramount importance is the warning regarding an increased risk of death, serious cardiovascular and thromboembolic events (e.
- g.
- , myocardial infarction, stroke, DVT, PE), and loss of vascular access patency in chronic kidney disease (CKD) patients when ESAs are administered to target hemoglobin levels exceeding 11 g/dL.
- Similarly, in cancer patients, an increased risk of death and/or tumor progression or recurrence has been observed in some clinical studies, particularly when ESAs are used to achieve hemoglobin levels above 12 g/dL.
- The decision to use epoetin beta in cancer patients should involve a careful discussion of these risks versus potential benefits.
- Pure Red Cell Aplasia (PRCA) with neutralizing antibodies to erythropoietin has been reported, requiring immediate discontinuation of the ESA and assessment.
- Blood pressure must be adequately controlled prior to and during treatment due to the risk of exacerbating hypertension.
- Seizures have been reported, particularly at the start of therapy.
- Patients should be regularly monitored for iron status, and iron supplementation is often required to ensure optimal therapeutic response and prevent functional iron deficiency.
- Any signs of allergic reactions necessitate immediate medical attention.
How it Works (Mechanism of Action)
Epoetin beta is a recombinant human erythropoietin, structurally and functionally analogous to the endogenous erythropoietin hormone produced primarily by the kidneys. Its primary mechanism of action involves binding to specific erythropoietin receptors located on the surface of erythroid progenitor cells within the bone marrow. This binding initiates a signaling cascade that promotes the proliferation, differentiation, and maturation of these progenitor cells into reticulocytes and subsequently into mature red blood cells. By stimulating erythropoiesis, epoetin beta effectively increases the red blood cell mass, hemoglobin concentration, and hematocrit, thereby counteracting anemia. In conditions like chronic renal failure, where endogenous erythropoietin production is deficient, epoetin beta directly replaces the missing hormone. In other anemic states, it can augment insufficient natural production or overcome erythropoietic suppression. This targeted stimulation of red blood cell production leads to improved oxygen-carrying capacity of the blood and alleviates the symptoms associated with anemia, such as fatigue and shortness of breath and improves patient quality of life.
Commercial Brands (Alternatives)
No other brands found for this formula.